![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1475, 2005-01, pp. : 11-12
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
TAC regimen improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1424, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Trastuzumab improves survival in early breast cancer
Inpharma, Vol. 1, Iss. 1490, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adjuvant regimen with docetaxel best bet in operable breast cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 480, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Adjuvant regimen with docetaxel best bet in operable breast cancer
Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Docetaxel delivers over doxorubicin for early breast cancer
Inpharma, Vol. 1, Iss. 1620, 2008-01 ,pp. :